There are two new MCADD trials that have started in recent months. One explores the use Dojolvi (triheptanoin) and the second the use of phenylbutyrate with MCADD patients. Join MitoAction as Dr. Arnold discusses the science behind both studies, why these substances are being evaluated, and what these studies will look like. If you have any questions about the trials or about participating in either trial, we encourage you to come, learn, and bring your questions!
Dr. Arnold graduated from Indiana University with degrees in biology and chemistry and has a Master's degree in Medical Genetics from Indiana University-Purdue University in Indianapolis. She graduated from medical school at Upstate Medical University and completed a residency in Pediatrics at Northwestern University. Her genetics training was at the University of Colorado, and she is boarded in Clinical Biochemical Genetics and Clinical Genetics.
Dr. Arnold was Clinical Director and, most recently, Clinical Research Director at the University of Pittsburgh. She is an Emeritus Professor and a consultant with Virtual Medical Practice. Dr. Arnold is the past president of the Society for Inherited Metabolic Disorders and the recipient of the Shapira Award for the best member’s paper in Molecular Genetics and Metabolism. She has a long-standing interest in fatty acid oxidation disorders, working with Dr. Vockley for 13 Years.